A new guideline advises most patients to continue GLP-1 drugs before surgery. The FDA warns against California-made ...

Vas Narasimhan is global head of drug development and chief medical officer at Novartis, and spoke to pharmaphorum at the company’s recent Q4 results conference.

Novartis CEO Vas Narasimhan said: "I would like to thank Liz for her leadership and her contributions to our business and our patients this past year. She made a significant positive impact on the ...

As it stands, Sandoz will be listed on the SIX Swiss Exchange, with an American Depositary Receipt (ADR) programme in the US, although Novartis chief executive Vas Narasimhan said this morning he ...

Novartis has been streamlining its business since CEO Vas Narasimhan took over, and has continued that push with the divestment of three drugs to Recordati for $390 million upfront. The Italian ...

New CEO Vas Narasimhan wants to cut Novartis' R&D costs by using digital tech – and with this in mind the firm has scaled up a project involving virtual clinical trials. The Swiss pharma company ...

Novartis chief executive Vas Narasimhan said the partnership “will help us deliver on our purpose to reimagine medicine to improve and extend lives,” while his counterpart at Microsoft ...

Novartis CEO Vas Narasimhan said: “Passionate start-ups and entrepreneurs are the vanguard of health tech. We want to work together to translate that innovation into real solutions for patients.” ...

Novartis said this morning that Bradner (pictured ... could see a headcount reduction of 8,000 as chief executive Vas Narasimhan chases down $1.5 billion in cost reductions.

Tesla sold 68,280 China-made vehicles in October, a 5.3% drop from the previous year, with Model 3 and Model Y deliveries down 22.7% month-over-month. Tesla extended its interest-free financing for ...